journal article·2026-05-20Open access

SSR4 sustains Tertiary Lymphoid Structures by Regulation Quality Control of N‐linked Glycosylation During B‐cell Differentiation Into Plasmacyte in Colorectal Cancer

Wei Zhao, Youcai Zhao, Haiyang Li, Bowen Yang, Siyan Lu, Xueting Fu, Caixia Zhang, Yirong Chen, Xiaofeng Bian, Xinghua Ma, Xiaobing Yang, Bin Wang, Yuan Fang, Lulu Yang, Yelin Zhao, Shuli Zhao

Abstract

ABSTRACT Intratumoral tertiary lymphoid structure (TLS) fosters B‐cell differentiation and antibody production, yet the intrinsic programs sustaining these functions remain unclear. By integrating spatial transcriptomics and single‐cell RNA sequencing of colorectal cancer, we delineate a B‐cell trajectory enriched for endoplasmic reticulum protein processing, autophagy, NF‐κB signaling, and N‐linked glycosylation, highlighting SSR4 as a progressively induced TRAP‐complex component. SSR4 is further upregulated in B cells from anti‐PD‐1 responders. B‐cell‐specific Ssr4 deletion leads to peripheral B‐cell loss, reduced antibody output, exacerbated colitis, and impaired mucosal immunity. Mechanistically, SSR4 interacts with DDOST to regulate BAFFR N‐glycosylation, thereby sustaining B‐cell activation and LTα1β2 expression via NF‐κB signaling. In Apc Min/+ mice, Ssr4 deficiency accelerates tumorigenesis, disrupts TLS maturation, lowers serum IgG1, and increases high‐mannose (HM) Ig. Conversely, SSR4 overexpression in CHO cells reduces high‐mannose glycans and enhances IgG1 ADCC and CDC. These findings identify SSR4 as a central regulator of B‐cell glycosylation and TLS‐dependent anti‐tumor immunity, offering translational implications for immunotherapy and antibody engineering.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: T-cell and B-cell Immunology · Glycosylation and Glycoproteins Research · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu China

Department of General Surgery Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu China

General Clinical Research Center Nanjing First Hospital China Pharmaceutical University Nanjing Jiangsu China

General Clinical Research Center Nanjing First Hospital Nanjing Medical University Nanjing Jiangsu China

Division of ENT Diseases Department of Clinical Science Intervention and Technology (CLINTEC) Karolinska Institutet Stockholm Sweden

Funding

National Natural Science Foundation of China

References (47)

Show source-provided references
1. 10.1038/s41423‐018‐0027‐x10.1038/s41423‐018‐0027‐x ↗
2. 10.1038/s43018‐021‐00232‐610.1038/s43018‐021‐00232‐6 ↗
3. 10.1158/1078‐0432.CCR‐20‐358610.1158/1078‐0432.CCR‐20‐3586 ↗
4. 10.21037/jgo‐22‐71710.21037/jgo‐22‐717 ↗
5. 10.1016/j.molimm.2007.07.02910.1016/j.molimm.2007.07.029 ↗
6. 10.1080/1040923059100816110.1080/10409230591008161 ↗
7. 10.1016/j.cub.2019.01.00310.1016/j.cub.2019.01.003 ↗
8. 10.3390/biom1004062410.3390/biom10040624 ↗
9. 10.1093/glycob/cwy09310.1093/glycob/cwy093 ↗
10. 10.1098/rsob.19024410.1098/rsob.190244 ↗
11. 10.1080/14737159.2022.201901510.1080/14737159.2022.2019015 ↗
12. 10.1016/j.ymgme.2024.10847710.1016/j.ymgme.2024.108477 ↗
13. 10.1080/2162402X.2021.196976710.1080/2162402X.2021.1969767 ↗
14. 10.1126/sciadv.abc636410.1126/sciadv.abc6364 ↗
15. 10.1126/science.adj485710.1126/science.adj4857 ↗
16. 10.1016/j.cell.2024.10.03510.1016/j.cell.2024.10.035 ↗
17. 10.1093/hmg/ddt55010.1093/hmg/ddt550 ↗
18. 10.1038/s41422‐019‐0174‐310.1038/s41422‐019‐0174‐3 ↗
19. 10.1016/j.imlet.2023.05.00610.1016/j.imlet.2023.05.006 ↗
20. 10.1016/j.ccell.2024.06.00910.1016/j.ccell.2024.06.009 ↗
21. 10.1126/science.aap931010.1126/science.aap9310 ↗
22. 10.1016/j.cell.2023.10.02210.1016/j.cell.2023.10.022 ↗
23. 10.1126/science.abn893410.1126/science.abn8934 ↗
24. TRAF3‐EWSR1 signaling Axis Acts as a Checkpoint on Germinal Center Responses10.1084/jem.20221483 ↗
25. 10.1126/sciadv.aaw031510.1126/sciadv.aaw0315 ↗
26. 10.1038/s41422‐018‐0055‐110.1038/s41422‐018‐0055‐1 ↗
27. 10.1172/JCI15345410.1172/JCI153454 ↗
28. 10.1038/s41590‐025‐02102‐010.1038/s41590‐025‐02102‐0 ↗
29. 10.1038/s41590‐024‐01808‐x10.1038/s41590‐024‐01808‐x ↗
30. 10.1016/j.cell.2024.03.03810.1016/j.cell.2024.03.038 ↗
31. 10.1016/j.celrep.2022.11101910.1016/j.celrep.2022.111019 ↗
32. 10.4049/jimmunol.181.2.97610.4049/jimmunol.181.2.976 ↗
33. 10.1073/pnas.240430912110.1073/pnas.2404309121 ↗
34. 10.1023/A:102659851668110.1023/A:1026598516681 ↗
35. 10.1016/j.immuni.2022.11.01410.1016/j.immuni.2022.11.014 ↗
36. 10.1158/2159‐8290.CD‐22‐140110.1158/2159‐8290.CD‐22‐1401 ↗
37. 10.1038/s41467‐018‐05770‐910.1038/s41467‐018‐05770‐9 ↗
38. 10.1016/j.cellimm.2018.07.00710.1016/j.cellimm.2018.07.007 ↗
39. 10.1016/j.cellimm.2018.11.00610.1016/j.cellimm.2018.11.006 ↗
40. 10.1016/j.it.2023.06.00410.1016/j.it.2023.06.004 ↗
41. 10.1172/JCI13002910.1172/JCI130029 ↗
42. 10.1038/s41580‐020‐00294‐x10.1038/s41580‐020‐00294‐x ↗
43. 10.1371/journal.ppat.101098910.1371/journal.ppat.1010989 ↗
44. 10.1038/s41598‐023‐42178‐y10.1038/s41598‐023‐42178‐y ↗
45. 10.1007/s10875‐023‐01429‐310.1007/s10875‐023‐01429‐3 ↗
46. 10.1016/j.immuni.2022.11.00210.1016/j.immuni.2022.11.002 ↗
47. 10.1038/s41590‐023‐01540‐y10.1038/s41590‐023‐01540‐y ↗